Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies

On October 23, 2024 Interius BioTherapeutics, a clinical-stage company engineering targeted, programmable vectors for the precision delivery of genetic medicines, reported that the first study participant has been dosed in INVISE, its first-in-human Phase 1 clinical trial of INT2104, a first-in-class gene therapy that delivers a CAR transgene to generate effector CAR-T and CAR-NK cells in vivo for the targeting of CD20-positive B cells for the treatment of B-cell malignancies (Press release, Interius BioTherapeutics, OCT 23, 2024, View Source [SID1234647336]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Interius was founded with a sense of urgency to provide patients with a new therapeutic option that does not require preconditioning or long manufacturing and wait times. Interius’s breakthrough technology allows precise targeting of gene therapies to specific cells via intravenous administration," said Interius President and CEO, Phil Johnson, M.D. "This milestone marks the first time that a durable in vivo CAR therapy has been used in the clinic. INT2104 has the potential to overcome ex vivo CAR therapy challenges with a single-dose, off-the-shelf, widely accessible therapy for the treatment of B cell malignancies enabled by Interius’s programmable platform. In our preclinical studies, we achieved successful B cell depletion in small and large animal models without chemotherapy and observed no signs of cytokine release syndrome (CRS) or neurotoxicity. We look forward to sharing interim clinical safety and proof-of-concept data at a scientific meeting next year."

Dr. Michael Dickinson, MBBS, FRACP, Lead of the Aggressive Lymphoma Disease Group at Peter MacCallum Cancer Centre and Royal Melbourne Hospital and INVISE Principal Investigator, added, "The need for new, accessible treatment options for patients with cancer is critical. Innovative approaches, like in vivo CAR gene therapies, have the potential to transform how we treat cancer, offering faster, single-dose solutions that are less burdensome on patients and treatment centres."

About INVISE
INVISE (INjectable Vectors for In Situ Engineering) is a first-in-human Phase 1 clinical trial evaluating the safety of INT2104 intravenous infusion in adults with refractory/relapsing B cell malignancies. The study is a global, two-part, multicenter, open-label, single dose design with a dose escalation portion designed to inform the dose of INT2104 to be used in the dose confirmation part of the trial and future studies. INVISE has been granted Human Research Ethics Committee (HREC) approval and Clinical Trial Notification (CTN) clearance by the Australian Therapeutic Goods Administration (TGA). Additional information and enrollment criteria may be found on clinicaltrials.gov (NCT06539338).

About INT2104
INT2104 is a wholly-owned investigational gene therapy candidate, which specifically targets CD7-positive T and NK cells and delivers a CAR transgene to create effector CAR-T and CAR-NK cells in vivo. The CAR cells target CD20-positive B cells for the treatment of B cell malignancies. Unlike ex vivo CAR-T therapies, INT2104 is an off-the-shelf, single dose treatment, administered systemically through intravenous infusion without the need for lymphodepletion or for any special equipment or training.

HotSpot Therapeutics Presents Preclinical Data from MALT1 CBM Signalosome Glue Program at 36th EORTC-NCI-AACR Symposium

On October 23, 2024 HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," reported it will present preclinical data from the Company’s mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) CARD11-BCL10-MALT1 (CBM) signalosome glue program highlighting its potential in NF-kB-driven solid tumors in a poster presentation at the 36th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium (Press release, HotSpot Therapeutics, OCT 23, 2024, View Source [SID1234647352]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MALT1 is a component of the CBM protein complex, which serves as a key regulator of NF-kB signaling in cells, including B and T cells. MALT1 is implicated in a range of hematological malignancies and solid tumors. Leveraging the Company’s proprietary Smart AllosteryTM platform, HotSpot has developed a potential first-in-class small molecule signalosome glue designed to selectively inhibit the scaffolding function of MALT1, a dominant driver of the NF-kB pathway, while sparing MALT1’s protease function.

"Our proprietary Smart Allostery platform has enabled the development of a MALT1 signalosome glue designed to selectively inhibit MALT1’s scaffolding function, a distinct activity profile that enables deep inhibition of the NF-kB pathway," said Geraldine Harriman, Ph.D., Chief Scientific Officer of HotSpot Therapeutics. "As the NF-kB signaling pathway is a well-characterized oncogenic driver, these preclinical data lend support for HST-1021’s potential utility for NF-kB-driven tumors, including as a precision oncology approach for solid tumors mediated by this pathway."

The presentation describes preclinical data for HST-1021, HotSpot’s MALT1 CBM signalosome glue development candidate:

In contrast to MALT1 protease inhibitors, HST-1021 demonstrated robust inhibition of CBM signalosome activity.
In an NF-kB-driven nasopharyngeal carcinoma patient-derived xenograft model, HST-1021 demonstrated dose-dependent anti-tumor activity, supporting HST-1021’s potential for the treatment of NF-kB-driven solid tumors.

Be Bio Announces $82 Million Financing and Transition to Clinical Stage Company

On October 22, 2024 Be Biopharma, Inc. ("Be Bio" or "the Company"), a leader in the discovery and development of engineered B Cell Medicines (BCMs), reported key milestones alongside a new round of funding as its lead program, BE-101 for Hemophilia B, enters the clinic, and its second development candidate for Hypophosphatasia is unveiled (Press release, Be Biopharma, OCT 22, 2024, View Source [SID1234647301]). Both programs are built on Be Bio’s powerful and efficient BCM platform, which utilizes gene editing to engineer B cells to produce sustained levels of therapeutic proteins, resulting in durable, titratable, and redosable candidates that require no preconditioning and have the potential to become best-in-class genetic medicines.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key recent milestones include:

BE-101: Phase 1/2 BeCoMe-9 Trial Open for Patient Enrollment; Granted Fast Track Designation. In May 2024, Be Bio announced that BE-101, a first-in-class BCM, received clearance of its Investigational New Drug application. BE-101 is designed to produce constant levels of Factor IX in a durable, redosable, and titratable manner, without the need for preconditioning. BeCoMe-9 is a multi-center, first-in-human dose escalation study aimed at evaluating the safety and preliminary efficacy of BE-101 in adults with moderately severe to severe Hemophilia B. FDA has recently granted BE-101 Fast Track Designation.
BE-102 Nominated as a Development Candidate for Hypophosphatasia (HPP): BE-102 has been selected as a development candidate for the treatment of Hypophosphatasia (HPP), a severe genetic disease with very high unmet medical need, affecting approximately 50,000 patients. HPP is characterized by loss of function mutations in the ALPL gene which lead to deficient alkaline phosphatase (ALP) activity, resulting in weakened and underdeveloped bones and teeth. The only approved therapy for HPP requires multiple injections per week and is limited to pediatric-onset forms of the disease. Data presented at the 2024 American Society for Bone and Mineral Research (ASBMR) Meeting showed that BE-102 has the potential to generate active and sustained levels of ALP in vivo.
$82 Million Financing to Advance BE-101 to Clinical Proof of Concept and Progress BE-102: The Company has closed an $82 million financing, with backing from top venture capital firms and pharmaceutical companies, including ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb, and Takeda Ventures. The funds will be used to achieve clinical proof of concept for BE-101 and to advance the development of BE-102.
Key Hires in Clinical Development and Commercial: The Company is excited to welcome Suha Patel as Senior Vice President of Commercial & Franchise Strategy and Kiran Patki, MD as Senior Vice President of Clinical Development. Ms. Patel joins from Roche/Genentech, where she led the successful launch of Hemlibra and held senior roles across marketing, medical marketing and sales. Dr. Patki joins from Rally Bio, where he served as Senior Vice President and Global Team Leader for asset development projects, with prior leadership experience at Alexion Pharmaceuticals. Concurrent with building out these later-stage functions, the Company will streamline its early research organization and related functions to focus resources on product development.
"Advancing two BCMs that harness the potential of this new modality represents an exciting step in transforming the treatment landscape for their respective indications with potentially best-in-class genetic medicines. With support from a top-tier syndicate of investors and pharmaceutical companies, we are eager to clinically demonstrate BE-101’s potential to provide a highly durable FIX replacement therapy for Hemophilia B patients. Additionally, we are excited to advance BE-102 to address the needs of a large patient population with few to no therapeutic options," said Joanne Smith-Farrell, Ph.D., Chief Executive Officer of Be Bio. "As we build out the team to support product development, we are delighted to welcome Suha and Kiran, experienced leaders who bring deep development and commercial expertise to our team, further strengthening our leadership as we transition into a clinical-stage company."

Dr. Smith-Farrell added: "Our innovative and highly effective research team is the driving force behind the creation of BE-101 and BE-102. They quickly brought the BCM platform to life, achieving IND clearance for BE-101 in just 2.5 years from the program’s inception, and advancing BE-102 to DC in only 15 months, showcasing the platform’s versatility and modularity. As we shift resources toward product development, some valued colleagues will be moving on. We are incredibly proud of their achievements and deeply grateful for their tireless and impactful work on behalf of Be Bio and the patients whose lives we hope these therapies will one day transform."

About BE-101

BE-101 is a first-in-class BCM that is engineered to insert the human Factor IX (FIX) gene into primary human B cells, allowing for continuous expression of active FIX for the treatment of hemophilia B. BE-101 has the potential to express sustained therapeutic FIX activity levels with a single infusion while having the flexibility to be titrated and/or re-dosed, and without the need for preconditioning. The potential to maintain therapeutic FIX activity levels while the reducing dosing frequency associated with current FIX replacement regimens could address the considerable infusion burden associated with current therapies and potentially drive reductions in the annualized bleeding rates and FIX usage. The US FDA cleared the BE-101 IND in May of 2024, and granted Fast Track designation in September of 2024. The Phase 1/2 BeCoMe-9 Trial has been initiated and further details of the trial can be found at www.clinicaltrials.gov under NCT identifier: NCT06611436.

About Hemophilia B

Hemophilia B is an X-linked recessive bleeding disorder that affects approximately 40,000 people globally. It is caused by mutations in the gene that encodes for the FIX protein, an essential enzyme in the coagulation cascade. This can lead to spontaneous bleeding as well as bleeding following injuries or surgery. People with hemophilia B bleed longer than other people. Bleeds can occur internally, into joints and muscles, or externally, from minor cuts, dental procedures or trauma. The current standard of care remains prophylactic administration FIX replacement therapy with a dosing frequency that ranges from every week to every 2 weeks. The short biological half-life of FIX requires lifelong frequent infusions to maintain therapeutic levels.

About BE-102

BE-102 is a first-in-class BCM that has been engineered using artificial intelligence-guided protein design to modify primary human B cells to produce ALP, an enzyme deficient in people living with HPP. A single infusion of BE-102 has the potential to express sustained therapeutic ALP with the flexibility to be titrated and/or re-dosed, if needed, and without the need for pre-conditioning. BE-102 has been selected as a Development Candidate and has the potential to transform the standard of care for people living with HPP.

About Hypophosphatasia

HPP is a genetic disease caused by loss of function mutations in the ALPL gene, leading to a deficiency in ALP activity that is required for healthy mineralization of bones and teeth. Insufficient levels of ALP result in the inability of calcium and phosphate to mobilize from the blood, resulting in weakened and underdeveloped bones and teeth. HPP is estimated to affect up to 50,000 people. There is only one approved therapy which requires three to six times a week administration.

About Engineered B Cell Medicines – A New Class of Cellular Medicines

The B cell is a powerful cell that produces thousands of proteins per cell per second at constant levels, and over decades. Precision genome editing can now be used to engineer B Cells that produce therapeutic proteins of interest, driving a new class of cellular medicines – Engineered B Cell Medicines (BCMs) – with the potential to be durable, allogeneic, redosable, and administered without pre-conditioning. The promise of BCMs could transform therapeutic biologics across protein classes, patient populations and therapeutic areas.

AbCellera to Present at Upcoming Investor Conferences in November 2024

On October 22, 2024 AbCellera (Nasdaq: ABCL) reported that executives from the Company will be presenting at the following investor conferences (Press release, AbCellera, OCT 22, 2024, View Source [SID1234647319]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel Healthcare Conference on Monday, November 18, 2024, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time)
Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:00 a.m. Pacific Time (5:00 p.m. Greenwich Mean Time)

Live audio webcasts of each presentation may be accessed through links that will be posted on AbCellera’s Investor Relations website. Replays of each webcast will be available through the same links following the presentations.

BullFrog AI’s VP Artificial Intelligence to Present at Google’s Cancer AI Symposium

On October 22, 2024 BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, reported its VP Artificial Intelligence, Enrique García-Rivera, Ph.D., will present at Google’s inaugural Cancer AI Symposium on October 30, 2024, at the Boston Center for the Arts (Press release, Bullfrog AI, OCT 22, 2024, View Source [SID1234647302]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. García-Rivera’s presentation will showcase BullFrog AI’s groundbreaking use of artificial intelligence in drug discovery and development. Highlighting the Company’s proprietary bfLEAP platform, the presentation will explore how multimodal biological data—including genomics, transcriptomics, and clinical data—are integrated to accelerate the drug development process.

A key aspect of the presentation will be how bfLEAP is applied to cancer research, leveraging AI to identify complex biological patterns that contribute to disease progression and treatment resistance. Dr. García-Rivera will also reference BullFrog AI’s collaboration with the Lieber Institute for Brain Development as a prime example of how bfLEAP is being utilized across various therapeutic areas. The collaboration, which focuses on neurological disorders such as bipolar disorder, underscores the platform’s versatility and potential to drive innovation across multiple domains, including cancer.

Dr. García-Rivera will also introduce BullFrog AI’s novel "AlgoLLM" system for gene prioritization, which revolutionizes the identification of high-priority targets in drug development by harnessing large language models. This innovative AI tool is critical for streamlining the discovery of actionable insights in neuropsychiatric disorders and other diseases, advancing the Company’s mission to develop more effective and personalized treatments.